Miracor Medical vs. Abbott Laboratories: LVAD Patent Dispute Consolidated in Illinois

Case Overview

The Parties

The Patents at Issue

This landmark dispute involves two U.S. patents covering technologies directly implicated in Abbott’s HeartMate 3 product line:

• • US12104600B2 (Application No. US18/363166) — Covers technologies in the cardiac assist or ventricular support domain, with claims relevant to LVAD system architecture.
• • US12117007B1 (Application No. US18/740119) — A related patent with claims directed at overlapping cardiac device functionality.

The Accused Products

Abbott’s accused products span the full HeartMate 3 ecosystem:

• • HeartMate 3 LVAD Blood Pump
• • HeartMate 3 LVAD/LVAS System
• • HeartMate Touch Communication System
• • HeartMate 3 System Controller
• • HeartMate System Monitor

Legal Representation

Both firms are recognized leaders in patent litigation, ensuring sophisticated advocacy on both sides.

Plaintiff (Miracor Medical): Barnes & Thornburg, LLP, with attorneys Craig D. Leavell, Mark A. Hagedorn, Paul T. Olszowka, and Todd G. Vare.

Defendant (Abbott Laboratories): Winston & Strawn, LLP, represented by Charles Bennett Klein, Nimalka Ratnavali Wickramasekera, and Saranya Raghavan.

The Verdict & Legal Analysis

Litigation Timeline & Procedural History

Case No. 1:25-cv-00484 was filed in the Northern District of Illinois — a venue with established patent litigation infrastructure and proximity to Abbott’s Illinois headquarters, making it a strategically logical choice for both parties. Abbott’s principal place of business within the district likely factored into venue selection, reducing jurisdictional challenges.

The case ran for 419 days before termination — a relatively compressed timeline for patent infringement litigation of this complexity. The termination, however, was procedural rather than substantive: the court consolidated this case with two parallel actions (Case Nos. 23 C 16257 and 25 C 15119) under Federal Rule of Civil Procedure 42(a)(2), consolidating all three for all purposes under the lead docket. This consolidation was entered without objection, suggesting both parties recognized judicial efficiency benefits.

Outcome

Case No. 1:25-cv-00484 was terminated via consolidation on March 10, 2026, pursuant to the court’s order in lead Case No. 23 C 16257. The consolidation was ordered under Federal Rule of Civil Procedure 42(a)(2), which permits courts to consolidate actions sharing common questions of law or fact to avoid unnecessary costs and delays.

Verdict Cause Analysis

The case was filed as a straightforward patent infringement action, with Miracor asserting that Abbott’s HeartMate 3 system and its associated components directly infringed claims under both patents-in-suit. The decision to consolidate — entered without objection — reflects a mutual recognition that the three related cases share sufficient factual and legal overlap to warrant unified management.

Legal Significance

The consolidation of three cases — spanning case numbers filed in 2023 and 2025 — reveals the longitudinal nature of Miracor’s patent assertion strategy against Abbott. This pattern is consistent with continuation patent prosecution, where a patent holder files continuation applications to generate new patent grants covering evolving commercial products.

Strategic Takeaways

For Patent Holders

Miracor’s approach — filing continuation applications to capture claims against commercially deployed products and pursuing parallel litigation across multiple case numbers — exemplifies a coordinated assertion strategy. Patent prosecutors in the medical device space should consider continuation planning aligned with competitive product releases.

For Accused Infringers

Abbott’s defense team at Winston & Strawn faces consolidated invalidity and non-infringement challenges across two patent families. Early investment in inter partes review (IPR) petitions at the USPTO could provide parallel validity challenges outside district court — a tactic worth evaluating given the recency of both patents-in-suit.

For R&D Teams

The breadth of accused products — covering the pump, controller, communication system, and monitor — underscores the importance of freedom-to-operate (FTO) analysis across entire product ecosystems, not just core implantable components. System-level IP risk assessment is essential for complex medical devices.

Industry & Competitive Implications

The Miracor v. Abbott dispute reflects a broader trend in medical device patent litigation: smaller, innovation-focused IP companies asserting patents against large commercial manufacturers whose products have achieved market dominance. Abbott’s HeartMate 3 represents a multi-hundred-million-dollar commercial franchise, making it a high-value litigation target.

For the LVAD and mechanical circulatory support sector, this case signals that IP risk in the space is not limited to legacy patents. Newly granted continuation patents — covering next-generation system architectures — present ongoing infringement exposure even for well-established products with extensive prior litigation histories.

The consolidation of three related cases also suggests the litigation may intensify before resolution. Companies in the cardiovascular device space — particularly those developing or commercializing next-generation LVADs, total artificial hearts, or cardiac assist systems — should monitor the consolidated proceedings in Case No. 23 C 16257 closely.

Licensing dynamics in this sector may also shift. If Miracor prevails on any infringement claim in the consolidated case, licensing pressure on other LVAD and cardiac assist device manufacturers could increase materially.

FAQ

What patents are involved in Miracor Medical v. Abbott Laboratories?

The dispute involves U.S. Patent Nos. US12104600B2 and US12117007B1, both directed at cardiac assist device technologies relevant to Abbott’s HeartMate 3 LVAD system.

Why was Case No. 1:25-cv-00484 terminated?

The case was terminated procedurally via consolidation under Federal Rule of Civil Procedure 42(a)(2) with two related cases under lead docket No. 23 C 16257. No merits determination has been issued.

How might this case affect LVAD patent litigation broadly?

The case reinforces the viability of multi-patent assertion strategies targeting integrated medical device ecosystems and signals ongoing IP risk for LVAD manufacturers from continuation patent portfolios.